Compass Pathways plans to charge for psilocybin by the dose, a few doses a year, at roughly what Spravato costs. The price may not be where the danger starts. The darker bottleneck is a six-hour session with no set rate.
Psychedelic medicine has sold itself as the anti-SSRI: no daily pill, no refills, a few supervised sessions and relief that lasts. Now Compass Pathways, whose psilocybin treatment COMP360 is in a rolling FDA review (Compass Pathways, 2026), has explained how it will charge. In September, its chief commercial officer, Lori Englebert, told investors the company will "likely price the product on a per dose basis" (Compass Pathways, Cantor Fitzgerald transcript, 2026). The target is an annual cost of about $50,000 to $65,000, the range Compass cites for Spravato, Johnson & Johnson's esketamine nasal spray for treatment-resistant depression (TRD) (Compass Pathways, Deutsche Bank transcript, 2026; MarketBeat, 2026). Compass expects patients to need two to four doses a year, about three on average (MarketBeat, 2026).
The industry that promised to end the refill is preparing to bring it back under another name.
That isn't hypocrisy; it is the arithmetic of a drug taken only a few times a year. Spread the annual target over about three doses and each one comes to roughly $17,000 to $22,000. Follow that number far enough, and it leads to the part of the business the sector would rather keep out of the light.
1. One and Done Was Never the Plan
The pricing follows the trials. Compass's first Phase 3 study, COMP005, tested a single dose followed by a 20-week blinded re-treatment phase; the second, COMP006, gave two fixed doses three weeks apart. Both then open into a re-dosing phase running to 52 weeks (ClinicalTrials.gov, NCT05624268/ NCT05711940). The second dose appears to matter. In COMP006, 39% of patients on 25 mg met Compass's response bar, against 25% after a single dose in COMP005, a comparison Compass says supports "the potential value of a second dose" (Compass Pathways, 2026). It expects its label to call for two initial doses (MarketBeat, 2026).
The rest of the field looks similar. Definium's LSD candidate, DT120, gives one dose in its Phase 3 anxiety trial, then a 40-week extension in which patients can be treated again (ClinicalTrials.gov/Definium Therapeutics, 2026). Otsuka's methylone, TSND-201, was given once a week for three to four weeks in its PTSD trials (ClinicalTrials.gov/Otsuka Pharmaceutical, 2026). All three programs build repeat dosing into the plan.
What is arriving is not a cure you pay for once. It is a low-frequency, high-intensity service: a few long, supervised sessions a year, billed each time the door closes. Priced that way, the right comparison isn't a one-time gene therapy. It's Spravato.
2. What Counts as Working
COMP360's headline figure counts a patient as a responder after a reduction of at least 25% on the Montgomery-Åsberg Depression Rating Scale (MADRS) (Compass Pathways, 2026). When Compass published its Phase 2 trial in the New England Journal of Medicine in 2022, response meant a drop of at least 50%, and remission meant a score of 10 or less. Response and remission at week 3 supported the trial's main result; sustained response at 12 weeks, meaning the bar was met at week 3 and at every visit after, did not (Goodwin et al., 2022).
Phase 3 frames durability more loosely. Compass reports that its week-6 responders maintained benefit on average through week 26, not that each stayed above the bar at every visit. Its remission figure is conditional: nearly 30% of those responders reached remission after retreatment (Compass Pathways, 2026). The fine print begins to matter when the bill climbs into five figures.
None of this makes COMP360 a failure. Both Phase 3 trials met their primary endpoints (Compass Pathways, 2026; Compass Pathways, 2025). COMP006 enrolled a very sick population, whose current episodes had lasted more than three years on average (PharmaTimes, 2026), and Compass presents the 25% threshold in that context (Compass Pathways, 2026). However, the headline bar moved, and the people who will notice are the ones deciding what to pay. An insurer asked for $17,000 to $22,000 a dose will read the threshold, not Compass's adjective for it, clinically meaningful.
3. Priced like Spravato, Judged like Ketamine
Pricing against Spravato is a bet on a precedent, and the precedent carries a warning label.
In 2019, the Institute for Clinical and Economic Review (ICER), an independent research institute, found that esketamine needed a 25% to 52% discount to reach a fair price, and rated it low value for money. Its chief medical officer called the price "an order of magnitude higher" than that of generic intravenous ketamine (ICER, 2019). The verdict did not stop the machine. By early 2026, Spravato's sales were running at more than $1.9 billion a year (Yahoo Finance, 14 Apr 2026). Even so, by Compass's count, it treats about 100,000 of roughly 4 million US patients with TRD (Compass Pathways, Deutsche Bank transcript, 2026).
What Spravato did get, and fast, was billing plumbing. It was approved in March 2019 (ICER, 2019). By January 2020, the Centers for Medicare & Medicaid Services (CMS) had created two dedicated codes, G2082 and G2083, on an interim final basis, paying for the visit, the observation period and the drug together (CMS, 2019).
Compass wants psilocybin judged against Spravato. ICER has already measured esketamine against ketamine, and the published economics of psilocybin describe a much cheaper product. One US model assumed a one-time, single-dose course of psilocybin-assisted therapy cost $5,000 and tested costs only up to $20,000. At $5,000, its authors concluded the therapy "may offer economic value"; at $10,000, it had a 1% probability of being cost-effective (Avanceña et al., 2025). A second US model found the therapy saved about $7,000 per patient, though its 30-year scenario credits each patient with almost 10 extra quality-adjusted life years (a standard measure of health gained), a benefit lasting far beyond any trial's follow-up (Ziadi & Park, 2026).
Compass's target is 2.5 to 3.3 times the highest cost that first model dared to test. The drug alone reaches that ceiling (MarketBeat, 2026); the six-hour session waits behind it as a second bill (Yahoo Finance, 15 Apr 2026).
4. The Code with No Price
Compass expects COMP360 to carry a safety program, known as a Risk Evaluation and Mitigation Strategy (REMS), comparable to Spravato's, with one key difference: monitoring. Spravato requires two hours after each dose; Compass expects COMP360 to require six (MarketBeat, 2026).
Annual cost:
Spravato: 50,000–65,000, as cited by Compass (MarketBeat, 2026);
COMP360: Targeting the same range (MarketBeat, 2026);
Dosing:
Spravato: Twice weekly during induction in its pivotal trial (Popova et al., 2019);
COMP360: Two to four doses a year, Compass estimates (MarketBeat, 2026);
Monitoring per dose:
Spravato: Two hours (MarketBeat, 2026);
COMP360: About six hours, Compass expects (MarketBeat, 2026);
Session billing:
Spravato: Dedicated Medicare codes since 2020 (CMS, 2019);
COMP360: Category III codes with no national rate (AAPC, 2025; BrainFutures, 2025; AMA, n.d.).
The codes for that time exist. In 2023, the American Medical Association (AMA) approved three codes, 0820T–0822T, for continuous in-person monitoring during psychedelic therapy; they took effect in 2024 (AAPC, 2025; BrainFutures, 2025). They are Category III codes, the AMA's tracking codes for emerging services (AMA, n.d.), and they bill by the hour: one for the lead clinician, one for a second clinician working concurrently, one for clinical staff (AAPC, 2025; BrainFutures, 2025). The code set anticipates two people in the room. Compass calls the codes "approved" and "live" and argues that, billed hour by hour, a psilocybin room should compare favorably with a Spravato room (Yahoo Finance, 15 Apr 2026).
Category III codes carry no relative value units (AMA, n.d.), the building blocks of Medicare's fee schedule (CMS, 2019). Payment, in the AMA's words, is "based on the policies of payers and not on a yearly fee schedule" (AMA, n.d.). Under Medicare, each regional contractor sets its own rate; private insurers decide individually whether and how much to pay (SIR IR Quarterly, 2023; Boston Scientific, 2025).
So, the drug will have a price, and the six hours will sit unpriced until each payer decides what they are worth. The launch depends on insurers paying for hours of clinician time under codes with no national value. That is the reimbursement problem, stated precisely: not the manufacturer's price but the provider's rate, the number waiting in the dark after the drug is sold.
5. What a Clinic Is Being Asked To Carry
The obvious launch sites are the clinics that already give Spravato. About 8,500 are certified, and the number is growing by roughly 500 a quarter (MarketBeat, 2026), but volume is concentrated: in April, Compass estimated that fewer than 1,000 sites account for 80% of it (Yahoo Finance, 15 Apr 2026). Those are the clinics that would have to make psilocybin work.
The arithmetic changes for them. With two hours of monitoring, a Spravato chair can turn over several times in a working day. With six, a psilocybin chair turns over once. And each psilocybin patient comes in far less often. Spravato patients in its pivotal trial came in twice a week during the four-week induction phase, then weekly or every other week (Popova et al., 2019); Compass expects COMP360 patients to need two to four doses a year (MarketBeat, 2026). That is the appeal for patients, and Compass acknowledges that some people on Spravato may want to switch because of the burden of frequent visits (Compass Pathways, Deutsche Bank transcript, 2026). For a clinic built on Spravato's schedule, it means far fewer billable visits per patient, each one much longer. Compass also plans to support buy-and-bill (Yahoo Finance, 15 Apr 2026), under which the clinic purchases the drug and then bills the insurer. At Compass's target, that means fronting roughly $17,000 to $22,000 per dose and waiting to be repaid, for a session whose main cost, clinician time, has no national rate.
The money and the risk sit in different places. Compass's revenue is set by its price. The clinic's depends on codes that each payer values differently, for a drug it may already have paid for. Compass's case is that hour-by-hour billing makes the room pay. It may. But the first clinics will learn the answer one payer, and one denied or underpaid claim, at a time.
6. Your Boss Pays First
TRD is expensive in ways an insurer never sees. A 2021 estimate, co-authored by researchers at Janssen, which sells Spravato, put TRD's annual US cost at $43.8 billion: $25.8 billion in health care and the other $18 billion in unemployment and lost productivity (Zhdanava et al., 2021). An insurer paying for psilocybin recovers, at most, the medical share.
Self-funded employers are different. They pay workers' health care directly from their own funds and also absorb the lost productivity, so both sides of the ledger sit on the same books. Two-thirds of covered workers, and 80% at larger firms, are in such plans (KFF, 2025). They are the natural first buyers of an expensive treatment with an absenteeism story. The catch is turnover: an employer can pay for the treatment and watch the benefit walk out the door with the employee.
7. Contracts Won't Fix Demand
Gene therapy shows the limits of clever contracts. BioMarin withdrew its hemophilia A gene therapy, Roctavian, in February 2026, saying the decision was unrelated to efficacy or safety and that it would honor its existing outcomes-based agreements with payers (BioMarin, 2026). It had already taken a $119 million inventory write-off in the fourth quarter of 2025, when it committed to the withdrawal (Fierce Pharma, 2026). Uptake had been sluggish amid doubts about the therapy's benefits and price, and Pfizer had already stopped selling its hemophilia B gene therapy, citing weak demand (BioPharma Dive, 2025). Roctavian had the outcomes-based contracts. The contracts weren't the problem; demand was. Compass is steering around that fight: it doesn't plan to target people already on Spravato, aiming instead at the far larger untreated market (Compass Pathways, Deutsche Bank transcript, 2026; MarketBeat, 2026).
8. Washington Did Everything Except Pay
Executive Order 14401, signed April 18, 2026, told FDA to grant national priority vouchers, set up a Right to Try pathway, committed at least $50 million to state programs, and directed the Attorney General to start rescheduling reviews once products complete Phase 3 (Exec. Order 14401, 2026; Penn LDI, 2026). The DEA already has a statutory 90-day deadline to reschedule after approval (Petrie-Flom Center, 2026).) Six days later, FDA gave vouchers to Compass, Usona, and Transcend (which Otsuka has since acquired), under a program that targets decisions within one to two months (Mind Medicine Law, 2026). In July, the Health Resources and Services Administration asked how psychedelic therapies could be delivered in ambulatory clinics and how to train the workforce (HRSA, 2026).
None of it sets a payment rate. Compass describes payer feedback as "overwhelmingly positive" (MarketBeat, 2026). Enthusiasm for a drug is not a rate for a session. It is not a check a clinic can cash.
The fix has a precedent and a date. Spravato was approved in March 2019 (ICER, 2019) and had its Medicare codes in the fee schedule rule finalized that November (CMS, 2019). A Medicare code wouldn't bind private insurers, which may pay a percentage of Medicare's rates or use other methods (SIR IR Quarterly, 2023; Boston Scientific, 2025), but it would give every payer a number. Compass expects to complete its FDA filing in the fourth quarter of 2026 (Compass Pathways, 2026). If the voucher timeline holds, a decision would come in early 2027, and, on the usual annual cycle, the next fee schedule rule would follow around November 2027.
That is the test. If CMS writes a code that pays for six hours of monitoring, the market exists. If it doesn't, the first clinics will be running a six-hour service on a two-hour rate card. They may open the room anyway. They will not keep it open for long.
References
- Compass Pathways (2026). "Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile," press release, 7 July 2026.
- Compass Pathways (2026). Cantor Fitzgerald Global Healthcare Conference, transcript, Investing.com, September 2026.
- Compass Pathways (2026). Deutsche Bank Healthcare Summit, transcript, Investing.com, September 2026.
- MarketBeat (2026). "Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances," via Yahoo Finance, 23 September 2026.
- ClinicalTrials.gov. NCT05624268 (COMP005) and NCT05711940 (COMP006).
- ClinicalTrials.gov / Definium Therapeutics (2026). NCT06741228 (Voyage); Voyage topline results, 12 August 2026.
- ClinicalTrials.gov / Otsuka Pharmaceutical (2026). NCT05741710 and NCT06215261; completion of Transcend Therapeutics acquisition, June 2026.
- Goodwin, G.M., et al. (2022). "Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression." N Engl J Med 387:1637-48. doi:10.1056/NEJMoa2206443.
- Compass Pathways (2025). "Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360," press release, June 2025.
- PharmaTimes (2026). "Compass Pathways reports six-month data confirming durable profile of COMP360," 7 July 2026.
- ICER (2019). "Final Report and Policy Recommendations on Esketamine for Treatment-Resistant Depression," 20 June 2019.
- Yahoo Finance (2026). "Johnson & Johnson's Spravato sales growth signals upside for psychedelics peers," 14 April 2026.
- CMS (2019). CY 2020 Physician Fee Schedule final rule and interim final rule, 84 Fed. Reg. 62568, 15 November 2019.
- Avanceña, A.L.V., Vuong, L., Kahn, J.G., & Marseille, E. (2025). Transl Psychiatry 15:330. doi:10.1038/s41398-025-03556-4.
- Ziadi, Y., & Park, T. (2026). Value Health Reg Issues. doi:10.1016/j.vhri.2026.101605.
- Yahoo Finance (2026). "Compass Pathways Touts Phase 3 COMP360 Depression Data, Eyes Rolling NDA and 2026 Launch Readiness," 15 April 2026.
- Popova, V., et al. (2019). Am J Psychiatry 176:428-38. doi:10.1176/appi.ajp.2019.19020172.
- AAPC (2025). "Legitimizing Psychedelic Medication Therapy," February 2025; BrainFutures (2025). "Code Options for Psychedelic-Assisted Therapy: Quick Guide."
- American Medical Association (n.d.). "CPT Category III Codes Long Descriptors."
- SIR IR Quarterly (2023). "Coding Q&A: Category III CPT," October 2023; Boston Scientific (2025). AGENT coding guide.
- Zhdanava, M., et al. (2021). J Clin Psychiatry 82(2):20m13699. doi:10.4088/JCP.20m13699.
- KFF (2025). 2025 Employer Health Benefits Survey.
- BioMarin (2026). "BioMarin Voluntarily Withdraws ROCTAVIAN from the Market," 23 February 2026.
- Fierce Pharma (2026). "BioMarin pulls hemophilia gene therapy Roctavian," 25 February 2026.
- BioPharma Dive (2025). "Pfizer stops selling hemophilia gene therapy, citing weak demand," 21 February 2025.
- Exec. Order 14401, 91 Fed. Reg. 21709, 22 April 2026; Section 5 as quoted by Penn LDI (2026), 22 July 2026
- Petrie-Flom Center (2026). "A New Executive Order on Psychedelics: Q&A with I. Glenn Cohen and Mason Marks," 18 April 2026.
- Mind Medicine Law (2026). "Trump Psychedelics Executive Order: 2026 Explainer," May 2026.
- HRSA (2026). Request for Information on training and care delivery models for psychedelic therapies, Fed. Reg., 14 July 2026.